NCT03340129 2026-02-02
ABC-X
Melanoma Institute Australia
Phase 2 Recruiting
Clinical Trials
18 trialsNCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02374242 2025-12-10
ABC
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT02696993 2025-11-10
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05704933 2025-10-20
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT06712927 2025-09-08
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Stanford University
Phase 2 Recruiting
NCT07134842 2025-08-21
WinGlio-ipi
University College, London
Phase 1 Recruiting
NCT05341349 2025-07-30
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
Phase 1 Active not recruiting
NCT01703507 2025-05-16
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Thomas Jefferson University
Phase 1 Completed
NCT05012254 2025-04-09
NIVIPI-Brain
FundaciĆ³n GECP
Phase 2 Active not recruiting
NCT03458455 2023-11-01
TREATMENT
Oslo University Hospital
Unknown
NCT03563729 2023-07-13
MEMBRAINS
Herlev Hospital
Phase 2 Recruiting
NCT02115139 2022-11-08
GRAY-B
Grupo EspaƱol Multidisciplinar de Melanoma
Phase 2 Completed
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT02097732 2021-05-12
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT03297463 2018-08-01
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT02662725 2016-01-25
IPI+RTS
University Hospital, Lille
Phase 2 Completed
NCT02460068 2015-06-02
NIBIT-M2
Italian Network for Tumor Biotherapy Foundation
Phase 3 Unknown